Elfors Mostafa Attya, Helmy Magdy Galal Eldin, Mahmoud Hossam Eldin Abdelaziz, Hussein Maha Mohsen, Naguib Ahmed Mohamed, Ahmed Mohamed Bahaa El Din, Elbaz Hosam Samir Ibrahim, Aly Aly Mohamed Osama
Department of Internal Medicine, Hepatology and GIT Unit, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Department of General Surgery and Liver Transplantation, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
BMC Gastroenterol. 2025 Jun 25;25(1):440. doi: 10.1186/s12876-025-03911-1.
Cytomegalovirus (CMV), a common virus with double-stranded DNA, causes complications and occasional death post-liver transplantation. The pre-transplant donor's and recipient's serological status is the primary potential factor for CMV reactivation. Our research aimed to assess risk factors that predict the possibility of CMV infection in post-liver transplant patients.
This retrospective study included 194 adult patients with hepatitis C-related end-stage liver disease (ESLD) who received liver transplants at the Ain Shams Center for Organ Transplantation between January 2014 and December 2018. The data were collected and analyzed regarding demographics, lab results, surgery details, and post-transplant outcomes to determine the rate of post-transplant CMV infection and identify its risk factors.
The graft rejection was more common among recipients who developed CMV infection (31.8%) compared to those without infection (11.3%). CMV infection appeared to be more frequent among patients receiving cyclosporine-based immunosuppressive therapy. Recipients with higher Model for End-Stage Liver Disease (MELD) scores showed increased incidence of post-transplant CMV infection. CMV IgM seropositivity pre-transplant was associated with post-transplant CMV infection.
Cyclosporine-based immunosuppressants, younger recipient age, a higher MELD score, and pre-transplant positive CMV IgM status were found to be risk factors associated with post-transplant CMV infection. CMV infection appeared to be associated with graft rejection.
巨细胞病毒（CMV）是一种常见的双链DNA病毒，可导致肝移植后出现并发症甚至偶尔死亡。移植前供体和受体的血清学状态是CMV再激活的主要潜在因素。我们的研究旨在评估预测肝移植后患者CMV感染可能性的危险因素。
这项回顾性研究纳入了194例丙型肝炎相关终末期肝病（ESLD）成年患者，他们于2014年1月至2018年12月在艾因夏姆斯器官移植中心接受了肝移植。收集并分析了有关人口统计学、实验室检查结果、手术细节和移植后结局的数据，以确定移植后CMV感染率并识别其危险因素。
与未发生CMV感染的受者（11.3%）相比，发生CMV感染的受者中移植排斥更为常见（31.8%）。在接受基于环孢素的免疫抑制治疗的患者中，CMV感染似乎更为频繁。终末期肝病模型（MELD）评分较高的受者移植后CMV感染发生率增加。移植前CMV IgM血清学阳性与移植后CMV感染相关。
发现基于环孢素的免疫抑制剂、受者年龄较小、MELD评分较高以及移植前CMV IgM状态阳性是与移植后CMV感染相关的危险因素。CMV感染似乎与移植排斥有关。
